Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs....
Indivior Data Shows Rapid Initiation With Once-Monthly SUBLOCADE Significantly Improves Retention In Opioid Use Disorder Patients, Especially Among Fentanyl-Positive Participants; Study Also Administered Second SUBLOCADE Injection A Week Later Vs. Standard 28 Days, Enabling Patients To Achieve And Maintain Target Medication Levels More Quickly
Indivior的数据显示，使用每月一次的SUBLOCADE可以快速启动，显著改善成瘾患者的留存情况，特别是在芬太尼阳性参与者中；研究还在一周后与标准的28天相比，进行了第二次SUBLOCADE注射，使患者能更快地达到和维持目标药物水平。
- Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered second SUBLOCADE injection a week later vs. standard 28 days, enabling patients to achieve and maintain target medication levels more quickly.
- Presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference, this study highlights the potential of rapid initiation to transform the treatment of opioid use disorder.
- Data supporting the subcutaneous administration of SUBLOCADE to alternative injection sites including the thigh, upper arm, and buttocks vs current subcutaneous abdominal injection site, were also presented at CSAM.
- SUBLOCADE has received Priority Review designation from the U.S. Food and Drug Administration (FDA) to expand the label to include rapid initiation one hour after a single transmucosal buprenorphine dose as well as inclusion of alternative injection sites.
- 数据显示，使用每月一次的SUBLOCADE可以快速启动，显著改善成瘾患者的留存情况，特别是在芬太尼阳性参与者中。研究还在一周后与标准的28天相比，进行了第二次SUBLOCADE注射，使患者能更快地达到和维持目标药物水平。
- 在2024年加拿大成瘾医学学会（CSAM）会议上发布的这项研究，突显了快速启动的潜力，可以改变治疗成瘾的方法。
- 在CSAM上还介绍了支持将SUBLOCADE皮下注射到大腿、上臂和臀部等替代注射部位，与当前的皮下腹部注射部位相比。
- SUBLOCADE已获得美国食品和药物管理局（FDA）的优先审查指定，以将标签扩展到包括在单次粘膜丁派诺注射后一小时进行快速启动，以及替代注射部位的包括。
RICHMOND, Va., Nov. 19, 2024 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) last week shared results from a randomized, open-label sub-study in opioid-dependent participants seeking treatment, (NCT04995029) that demonstrates rapid initiation (RI) with SUBLOCADE (buprenorphine extended-release injection) for the treatment of OUD significantly improves treatment retention compared to standard initiation (SI). RI with SUBLOCADE in a single day may reduce barriers to treatment and improve patient retention especially those who frequently inject opioids or use fentanyl without increasing the risk of precipitated opioid withdrawal (POW) symptoms. The data were presented at the 2024 Canadian Society of Addiction Medicine (CSAM) conference in Hamilton, Ontario, Canada.
纳斯达克/伦敦证券交易所上市的Indivior PLC在弗吉尼亚州里士满上周分享了一个随机、开放标签的亚组研究成果，研究对象是寻求治疗的依赖阿片类物质的参与者（NCT04995029），这项研究表明，使用SUBLOCADE（丁派诺缓释注射剂）进行成瘾治疗的快速启动（RI）显著改善治疗留存率，相比标准启动（SI）。使用SUBLOCADE进行一日内的快速启动可能减少治疗障碍，改善患者的留存，尤其是那些频繁注射阿片类药物或使用芬太尼的患者，而不增加引发阿片类撤退症状（POW）的风险。这些数据是在加拿大安大略省汉密尔顿举办的2024年加拿大成瘾医学协会（CSAM）会议上展示的。
